• Executed major collaboration with Shanghai Cell Therapy Group to co-develop first-in-class CAR-T therapy for solid cancers
• Raised $2.8 million in placements, improved balance sheet, and reduced quarterly cash operating costs by 31%
• Advancing partnering opportunities for AD-214 and WD-34 assets

AdAlta Limited, a clinical-stage biotechnology company, has reported its key results for the first half of the 2026 financial year. The primary focus during the period was to formally launch AdCella's 'East to West' cellular immunotherapy operations, strengthen the company's balance sheet, and advance partnering opportunities for its AD-214 and WD-34 assets. AdCella, a subsidiary of AdAlta, executed a Development and Collaboration Agreement with Shanghai Cell Therapy Group Co Ltd to co-develop BZDS1901, a first-in-class PD1 armoured MSLN CAR-T therapy for mesothelioma and other solid cancers. BZDS1901 has demonstrated complete responses in advanced mesothelioma patients, with overall response rates substantially exceeding current standard of care. AdAlta also raised $2.8 million via placements, received $0.93 million in R&D Tax Incentive refunds, repaid its Radium RDTI advance loan facility, and reduced quarterly cash operating costs by 31%. The company continues to progress partnering opportunities for its AD-214 asset, a first-in-class protein therapeutic for fibrotic diseases, and its WD-34 i-body targeting malaria. Near-term milestones include securing additional financing for AdCella, completing a pre-IND meeting with the FDA, and advancing discussions to in-license a second product for AdCella's pipeline.

AdAlta is focused on advancing its 'East to West' cellular immunotherapy strategy through AdCella, as well as progressing partnering opportunities for its AD-214 and WD-34 assets. The company aims to continue strengthening its balance sheet and reducing operating costs to support these key initiatives.